Haemonetics Corporation Company Profile
NYSE: HAEHealth CareMedical/Dental InstrumentsUSD
Market open · Delayed 15 min · as of Oct 8, 2:43 PM ET
Haemonetics at a glance
Haemonetics Corporation (NYSE: HAE) is a Medical/Dental Instruments company in the Health Care sector headquartered in Boston, MA. Haemonetics is led by Mr. Christopher A. Simon and employs about 3,009 people. The company's shares have traded publicly since 1991.
At a market capitalization of $4.71 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0000313143, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Haemonetics do?
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Haemonetics Corporation
- Ticker
- NYSE: HAE
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Christopher A. Simon
- Employees
- 3,009
- Headquarters
- 125 Summer Street, Boston, MA, United States
- Phone
- 781 848 7100
- Website
- haemonetics.com
- IPO year
- 1991
- Market cap
- $4.71B
- SEC CIK
- 0000313143
Companies similar to Haemonetics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MMSIMerit Medical Systems Inc. | 85.41 | +0.37% | $5.10B | vs HAE |
| TFXTeleflex Incorporated | 123.88 | -0.48% | $5.25B | vs HAE |
| STVNStevanato Group S.p.A. | 19.28 | -0.82% | $5.27B | vs HAE |
| HTFLHeartflow Inc. | 46.84 | -5.12% | $4.07B | vs HAE |
| ICUIICU Medical Inc. | 156.52 | +0.31% | $3.91B | vs HAE |
| MMEDMiniMed Group Inc. | 19.63 | +2.69% | $5.52B | vs HAE |
| NVSTEnvista Holdings Corporation | 22.47 | -2.47% | $3.61B | vs HAE |
| PLSEPulse Biosciences Inc | 49.40 | +0.63% | $3.52B | vs HAE |